Posted: 11:18a.m. IST, June 28, 2012
Washington, June 28 (ANI): Researchers at Weill Cornell Medical College have developed and successfully tested in mice an innovative vaccine that blocks addictive nicotine chemicals from reaching the brain.
The scientists described how a single dose of their novel vaccine protects mice, over their lifetime, against nicotine addiction.
The vaccine is designed to use the animal's liver as a factory to continuously produce antibodies that gobble up nicotine the moment it enters the bloodstream, preventing the chemical from reaching the brain and even the heart.
As far as we can see, the best way to treat chronic nicotine addiction from smoking is to have these Pacman-like antibodies on patrol, clearing the blood as needed before nicotine can have any biological effect, said the study's lead investigator, Dr. Ronald G. Crystal, chairman and professor of Genetic Medicine at Weill Cornell Medical College.
Our vaccine allows the body to make its own monoclonal antibodies against nicotine, and in that way, develop a workable immunity, Dr. Crystal stated.
Previously tested nicotine vaccines have failed in clinical trials because they all directly deliver nicotine antibodies, which only last a few weeks and require repeated, expensive injections, Dr. Crystal explained.
Plus, this kind of impractical, passive vaccine has had inconsistent results, perhaps because the dose needed may be different for each person, especially if they start smoking again, he added.
While we have only tested mice to date, we are very hopeful that this kind of vaccine strategy can finally help the millions of smokers who have tried to stop, exhausting all the methods on the market today, but find their nicotine addiction to be strong enough to overcome these current approaches, he said.
Studies show that between 70 and 80 percent of smokers who try to quit light up again within six months, Dr. Crystal noted.
The researchers are preparing to test the novel nicotine vaccine in rats and then in primates-steps needed before it can be tested ultimately in humans.
Dr. Crystal said that, if successful, such a vaccine would best be used in smokers who are committed to quitting.
They will know if they start smoking again, they will receive no pleasure from it due to the nicotine vaccine, and that can help them kick the habit, he stated.
The new vaccine has been described in the journal Science Translational Medicine. (ANI)